Optimizing the Diagnosis of Parkinsonian Syndromes With <sup>123</sup>I-Ioflupane Brain SPECT.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30995085.
- Also identified by DOI 10.2214/AJR.19.21088.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<b>OBJECTIVE.</b> The purpose of this article is to provide a review of <sup>123</sup>I-ioflupane SPECT in the evaluation of suspected parkinsonian syndromes (PSs). This collection of diseases presents frequent diagnostic challenges, even by movement disorder and dementia specialists. <b>CONCLUSION.</b> The <sup>123</sup>I-ioflupane scan serves as an imaging biomarker of the status of presynaptic dopamine transporters (DATs) in the striatum. As a result of neuronal death, DATs are greatly reduced in patients with PS neurodegenerative disorders, whereas clinical mimics generally do not show striatal DAT loss. This provides a tremendous opportunity for <sup>123</sup>I-ioflupane to aid in the accurate and timely diagnosis of these patients and optimize their management.
Medical subject headings
- Corpus Striatum
- Diagnostic Uses of Chemicals
- Nortropanes
- Parkinsonian Disorders
- Tomography, Emission-Computed, Single-Photon